Logo

Novartis's Kymriah Receives EU Approval

Share this

Novartis's Kymriah Receives EU Approval

Shots:

  •  Post FDA approval in Aug 2017- Kymriah (tisagenlecleucel- formerly CTL019) receives EU approval for treatment of patients up to 25 years with (r/r)- second or later stage in B-cell acute lymphoblastic leukemia (ALL) and with (r/r) diffuse large B-cell lymphoma (DLBCL)
  • The approval is based on two global trials JULIET and ELIANA results: JULIET(N=93): ORR 52%- CR 40%- 12% PR- mOS 11.7 mos; ELIANA (N=75): 81% achieved OR- 80% still in remission at 6 mos- 60% CR- 20% with iCR- mOS 19.1 mos
  •  With EU approval- Kymriah first-of-its-kind in CAR-T (chimeric antigen receptor T cell) therapy- is also designated as orphan medicinal product and one of the PRIME-designated therapies in enhancing QoL

/ article | Ref: Novartis | Image:  Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions